419 related articles for article (PubMed ID: 31034960)
1. RNAi therapeutic and its innovative biotechnological evolution.
Weng Y; Xiao H; Zhang J; Liang XJ; Huang Y
Biotechnol Adv; 2019; 37(5):801-825. PubMed ID: 31034960
[TBL] [Abstract][Full Text] [Related]
2. Clinical advances of siRNA therapeutics.
Hu B; Weng Y; Xia XH; Liang XJ; Huang Y
J Gene Med; 2019 Jul; 21(7):e3097. PubMed ID: 31069898
[TBL] [Abstract][Full Text] [Related]
3. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
[TBL] [Abstract][Full Text] [Related]
4. Re-Engineering RNA Molecules into Therapeutic Agents.
Egli M; Manoharan M
Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
[TBL] [Abstract][Full Text] [Related]
5. Patisiran: First Global Approval.
Hoy SM
Drugs; 2018 Oct; 78(15):1625-1631. PubMed ID: 30251172
[TBL] [Abstract][Full Text] [Related]
6. The current state and future directions of RNAi-based therapeutics.
Setten RL; Rossi JJ; Han SP
Nat Rev Drug Discov; 2019 Jun; 18(6):421-446. PubMed ID: 30846871
[TBL] [Abstract][Full Text] [Related]
7. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
Kristen AV; Ajroud-Driss S; Conceição I; Gorevic P; Kyriakides T; Obici L
Neurodegener Dis Manag; 2019 Feb; 9(1):5-23. PubMed ID: 30480471
[TBL] [Abstract][Full Text] [Related]
8. Patisiran for the treatment of patients with familial amyloid polyneuropathy.
Rizk M; Tüzmen S
Drugs Today (Barc); 2019 May; 55(5):315-327. PubMed ID: 31131842
[TBL] [Abstract][Full Text] [Related]
9. siRNA therapeutics: a clinical reality.
Saw PE; Song EW
Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
[TBL] [Abstract][Full Text] [Related]
10. Vutrisiran: First Approval.
Keam SJ
Drugs; 2022 Sep; 82(13):1419-1425. PubMed ID: 35997942
[TBL] [Abstract][Full Text] [Related]
11. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
[TBL] [Abstract][Full Text] [Related]
12. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
[TBL] [Abstract][Full Text] [Related]
13. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
Conceição I
Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
[TBL] [Abstract][Full Text] [Related]
14. Strategies, design, and chemistry in siRNA delivery systems.
Dong Y; Siegwart DJ; Anderson DG
Adv Drug Deliv Rev; 2019 Apr; 144():133-147. PubMed ID: 31102606
[TBL] [Abstract][Full Text] [Related]
15. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
Traber GM; Yu AM
J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
[TBL] [Abstract][Full Text] [Related]
16. The Growing Class of Novel RNAi Therapeutics.
Traber GM; Yu AM
Mol Pharmacol; 2024 Jun; 106(1):13-20. PubMed ID: 38719476
[TBL] [Abstract][Full Text] [Related]
17. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
Holm A; Løvendorf MB; Kauppinen S
Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
[TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
Jing X; Arya V; Reynolds KS; Rogers H
Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
[TBL] [Abstract][Full Text] [Related]
19. RNAi for Developing Targeted Therapeutics--CHI's Third Annual Meeting.
Plane G
IDrugs; 2010 Jan; 13(1):20-2. PubMed ID: 20024842
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic siRNA: state of the art.
Hu B; Zhong L; Weng Y; Peng L; Huang Y; Zhao Y; Liang XJ
Signal Transduct Target Ther; 2020 Jun; 5(1):101. PubMed ID: 32561705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
